次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

ブラジルの医薬品市場2015-2025年

Brazilian Pharmaceutical Market Outlook 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年2月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文199ページになります。
商品コード:VGN351

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
ブラジルの医薬品市場は力強い拡大を続け、2019年には506億ドル規模に達すると予測されます。米国やEU諸国などの成熟市場に比してこの先10年間、相当速い成長が続く見込みで、2025年までには世界の主要市場の一つとなるでしょう。当レポートでは、ブラジルの医薬品市場規模予測(2015-2025)、治療分野別市場予測、ブラジル国内地域別の市場特性、市場動向分析、ブラジル国内製薬企業、参入している国際企業動向などを織り交ぜ、概略以下の構成でお届けいたします。

【レポート構成概要】
・ブラジルの医薬品市場、市場規模予測2015-2025年
・全199ページ、53個のデータ表、58個のグラフ類VGN351_Brazilian Pharmaceutical Market Outlook 2015-2025 Cover.jpg
・ブラジル地域別、市場特性情報

・セグメント別市場予測2015-2025
- 先発医薬品・処方薬(ワクチン、生物製剤予測データも別掲)
- ジェネリック・処方薬(バイオシミラー予測データ別掲)
- OTC薬

・治療分野別、医薬品市場予測2015-2025
- 中枢神経系(CNS)
- 心血管(CV)
- 消化器系とメタボリック疾患治療
- がん治療
- 感染症:抗感染薬(ワクチンおよび抗生物質)
- その他疾患(合算データ)

・市場動向
- 患者ニーズに対応する企業戦略
- ブラジル国内外の企業活動、M&A動向、新薬ローンチ、売上ランキングと市場シェア
- 人口動態、経済、疫学的動向。増加する医療ニーズ評価と対応方法
- サプライチェーン分析。医薬品卸売、流通、小売業者
- 政策、当局規制、価格と費用償還
- 医療提供改善への地域努力
- 医療保険(公的、民間)
- 技術、研究開発と製造
- 技術移転と知的財産権保護、偽造防止の取り組み
- 生物製剤、バイオシミラーへの需要増大
- ブラジル市場のポジショニング(対世界、南米、BRIC諸国)

・リーディング企業分析
(ブラジル国内企業10社(以下一部例示))
- EMS
- Hypermarcas
- Aché
- Eurofarma
- Cristália
- Libbs
- União Química.

(ブラジル市場参入の国際大手企業10社)
- Sanofi
- Novartis
- Roche
- Merck & Co.
- Pfizer
- Takeda
- Bayer

(ジェネリックおよびバイオシミラーの国際企業)
- Teva Pharmaceutical Industries
- Mylan
- Actavis
- Glenmark
- Valeant
- Glenmark
- Strides Arcolab
- Biocon.

・ブラジル国内企業オピニオンインタビュー:
- Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica

・調査結論

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Brazilian Pharmaceutical Market Outlook 2015-2025

Table of Contents

1. Report Overview

1.1 Brazil’s Pharma Market: Overview
1.2 Brazilian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Study
1.6 Who is This Investigation For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQs)
1.9 Some Associated Reports
1.10 About Visiongain

2. Introduction to the Brazilian Pharmaceutical Market, 2015-2025

2.1 The Brazilian Pharmaceutical Market Overview
2.2 Generics Segment Continues to Grow in Importance
2.3 CNS the Largest Therapeutic Area in 2014
2.4 Four Domestic Companies in the Top Ten in 2014

3. Why the Brazilian Market Matters: Global Market Context

3.1 Seventh-Largest Global Economy in 2014. Fifth-Largest by 2023
3.2 Sixth-Largest Pharmaceutical Market in the World in 2013. Fourth-Largest by 2016
3.3 Brazil Represented 40% of the Latin American Pharmaceutical Market in 2014
3.4 Brazil as Part of the Pharmerging and BRIC Markets

4. Organisation of the Brazilian Pharmaceutical Market

4.1 ANVISA: The Key Institutional Body
4.2 Important Agencies Include Sindusfarma and ABRAFARMA
4.3 26% Supplement SUS with Private Healthcare in 2014
4.4 CMED Announces Average Drug Price Increase of 3.35%
4.5 RENAME Drugs and the Farmácia Popular
4.6 Private Insurance Market Growing, but Costs for Insurers Rising
4.7 M&A Led Consolidation Continues in Wholesale and Retail Sectors
4.7.1 Celesio-Owned Panpharma Still the Top Distributor
4.7.2 2013 Acquisition Makes Profarma the Largest Mixed Distributor
4.7.3 Raia Drogasil, DPSP SA and Brasil Pharma are the Leading Companies in the Retail Sector
4.8 Marketing Spend in Brazil Approaches $5bn; New Rules on Drug Advertising

5. Healthcare Variations between the Brazilian Regions

5.1 Population, Pharmaceutical Market Share and GDP by Region
5.2 South East: 42% of the National Population and 53% of Pharmaceutical Market Revenues
5.3 South: The Smallest Region, but Second-Highest GDP
5.4 North East: Second-Highest Pharmaceutical Market Share but Lowest Per Capita GDP
5.5 North: Largest and Poorest Region, Represents Less Than 5% of the Pharmaceutical Market
5.6 Midwest: Landlocked Region with the Nation’s Capital and the Lowest Population

6. Breakdown of the Brazilian Pharmaceutical Market by Product Type, 2015-2025

6.1 Forecasts for the Patented Prescription, Generic and OTC Segments of the Market, 2015-2025
6.2 Patented Prescription Drugs Forecast - Dominant Segment of the Market, But for How Much Longer?
6.2.1 PDPs: a Flagship Programme by the MoH for Bringing Down Costs
6.2.2 At 55% More Expensive, Patented Products are Struggling to Hold off the Generics Revolution
6.3 Generic Drugs Segment Forecast 2015-2025 - Continued Rapid Growth
6.3.1 Generic Pharmaceuticals: Rapid Expansion Since 2000
6.3.2 Pró-Genéricos Anticipate 45% Market Capture
6.3.3 Similares Drugs and Patient Confidence in Generics
6.3.4 Counterfeits: 7-22% of Drugs in Latin America Believed to be Affected
6.3.5 New Anti-Counterfeiting Security Measures as Part of the SNCM Due to Start in 2015 and Become Fully Operational in 2016
6.3.6 Challenges for the Brazilian Generics Market
6.4 Brazilian Biologics Market
6.4.1 Biosimilars Market in Brazil to Double in Size by 2018
6.4.2 BiocadBrazil Signs PDP for Bevacizumab and Intends to Bring More Biosimilars to Brazil
6.5 OTC Segment Forecast 2015-2025
6.5.1 OTC Segment: Analgesics, Multivitamins and Other Consumer Health Products Favoured by Brazilians
6.5.2 Multivitamins Purchased by ~15% of Brazilians
6.5.3 Coming Out From Behind the Counter
6.5.4 From Analgesics to Erectile Dysfunction Treatments, Consumer Health Treatments Remain Prominent in the Market

7. Therapeutic Areas in the Brazilian Market, 2015-2025

7.1 Forecasts for CNS, Cardiovascular, Alimentary/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2025
7.2 The Rise of Non-Communicable Diseases
7.3 Market Forecast for CNS Conditions 2015-2025
7.3.1 CNS Conditions: Currently the Largest Therapeutic Area in Brazil, Disease Burden
Comparable to US
7.3.2 Domestic Companies Target OTC and Generic CNS Treatments- Particularly in Pain
Relief
7.3.3 Foreign Competition in the Analgesics Field
7.3.4 18.4% of Brazilians Have Suffered Depression in their Lives - Represents Major
Opportunity in Antidepressant Space
7.3.5 CNS Conditions: Drivers and Restraints
7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2025
7.4.1 Cardiovascular Diseases: Brazil’s Biggest Killer
7.4.2 Anti-hypertensives: One of the Nation’s Key Drugs- as 23% of Brazilians Suffer from
Hypertension
7.4.3 Decline of the Statins
7.4.4 Aché and Sanofi Among the Main Players in that Field
7.4.5 Cardiovascular Opportunity and Challenges
7.5 Forecast for Alimentary/Metabolic Therapeutic Area, 2015-2025
7.5.1 Alimentary/Metabolic Diseases: Affecting More Than a Quarter of Brazilians
7.5.2 Lack of Diabetes Awareness Still a Concern
7.5.3 Brazil to Localise Insulin Production by 2016
7.5.4 EMS’ Generic Esomeprazole an Important Addition
7.5.5 Capturing the Alimentary/Metabolic Disease Opportunity
7.6 Market Forecast for Cancer Medicines, 2015-2025
7.6.1 Cancer Treatment to Become the Biggest Therapeutic Area
7.6.2 ANS Introduces Significant Changes to Cancer Care from Private Health Insurance
Providers
7.6.3 Most Common Cancers in Brazil, 2014
7.6.4 Biosimilars to Help Widen Medicine Access
7.6.5 Cristália, Libbs, Roche, Sanofi, Novartis and Amgen Among the Key Players in the Field
7.6.6 Will the Oncology Therapeutic Area Realise its Potential?
7.7 Forecast for Infectious Diseases Therapeutic Area, 2015-2025
7.7.1 Infectious Diseases: Submarket Led by Vaccines and Antibiotics
7.7.2 Vaccines- Brazil not just Reliant on Multinationals, but also Innovating in its own Right
7.7.3 Brazil Managing HIV Despite IP Concerns
7.7.4 Chagas Disease and Other Infections – the Challenge
7.7.5 Infectious Disease: The Past for Brazilian Pharma?
7.8 Other Therapeutic Areas

8. Domestic Companies in the Brazilian Market, 2015-2025

8.1 The Top Ten Domestic Pharmaceutical Companies in Brazil, 2014
8.2 Purchase of Medley in 2009 Means Multinationals Still Own Bulk of Market
8.3 Domestic Firms Control 70% of Generics Market
8.4 EMS: Brazil’s Leading Pharmaceutical Company
8.4.1 Company Split into Similar, OTC, Hospital, Generic and Prescription Divisions
8.4.2 Full Production Capabilities and Significant R&D Capabilities
8.4.3 Legrand and Germed Key Subsidiaries of EMS
8.4.4 Targeting Expansion Oversees
8.5 Hypermarcas: Market Leader in OTC and Branded Generics
8.5.1 Neo Química: Ranked Third in the Generics Segment
8.5.2 Subsidiaries include Mantecorp, Brainfarma, Cosmed, DM Industria Farmacêutica
8.6 Medley: Foreign-Owned Generics Giant
8.7 Aché: A Major Acquisition Target in Brazil
8.7.1 Acheflan - the First Drug to be Developed in Brazil
8.7.2 Possible M&A in the Near Future?
8.7.3 A Large Domestic Merger an Alternative Possibility?
8.8 Eurofarma: Fifth Largest Domestic Company, with Plans to Cover 90% of Latin America
8.8.1 Relentless Latin American Acquisitions Policy
8.9 Teuto: Largest Pharmaceutical Complex in Latin America
8.9.1 Melcon Partnership and Other Growth Strategies for Teuto
8.10 Biolab Farmacêutica: Leader in the Cardiology Prescription Drugs Market
8.10.1 Joint Ventures with Merz and Emcure
8.10.2 Number of New Product Launches in 2013 and Current Pipeline in 2015
8.11 Cristalia: Largest Producer of Anaesthetics in Latin America
8.11.1 Approval From ANVISA to Produce Biosimilar Drugs
8.11.2 Leader in API Manufacturing
8.11.3 Involved in a Third of All PDPs
8.12 Libbs: Key Player in Cancer Treatment
8.12.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
8.13 União Química: Huge Annual Production Capacity
8.13.1 Agreement with Novartis and Possible Public Offering in 2015
8.14 Other Domestic Players Include Moksha8 and Laboratório Daudt Oliveira
8.15 Biosimilar Collaborations
8.15.1 Bionovis: Conglomerate Developing 8 Biosimilars and Aiming to Launch First Product in 2016
8.15.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
8.16 Other Biotech Players Include Biomm and Innova
8.17 Fiocruz: At the Heart of Multiple PDPs
8.18 ANVISA Reform of Brazilian Patent System

9. Multinational Companies in the Brazilian Market, 2015-2025

9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2014
9.2 Notable M&A Activity
9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
9.3.1 Group Companies Include Sanofi Pasteur and Genzyme - Overall Portfolio of Over 350
Products
9.3.2 Inventory Mishandling and Dip in 2013 Results
9.4 Novartis: Only Multinational to Produce APIs in Brazil
9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
9.5 Roche: No Regrets over Staying in Brazil
9.5.1 Oncology Opportunity and Herceptin Pricing/Reimbursement
9.6 Merck & Co. - Long-Standing Presence in the Brazilian Market
9.6.1 Five Factories and Covers Five Broad Therapeutic Areas
9.6.2 Gardasil Added to SUS in 2013
9.6.3 Joint Venture with Eurofarma and Cristália
9.7 Pfizer: Targeting Emerging Market Growth via M&A
9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
9.8 Takeda: Expanding its Brazilian Business Through Acquisitions and Aims to Launch New Drugs
9.8.1 Acquisitions of Nycomed and Multilab and Global Restructuring
9.9 Bayer: Brazil the Fifth-Largest Market for Diversified German Giant
9.9.1 OTC a Major Focus in Brazil
9.10 AstraZeneca Targets Latin America
9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
9.11.1 Looking to Acquire OTC Brands
9.11.2 Technology Transfer Deal for Sifrol
9.12 Merck KGaA : Present in Brazil since 1923; Signs PDP with Bionovis for 8 Biosimilars.
9.12.1 Two Divisions and Multiple Therapeutic Fields
9.13 Other Notable Multinationals in Brazil
9.13.1 GlaxoSmithKline: Vaccines and Technology Transfer Opportunities
9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
9.13.2.1 Abbott: Generics and Diagnostics-Led Growth Strategy
9.13.3 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
9.13.4 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
9.13.5 Baxter: Entering Brazilian Haemophilia Market via Tech Transfer
9.13.6 Johnson & Johnson: Focusing on Consumer Health and Commodities
9.13.7 BiocadBrazil Farmaceutica
9.13.8 Amgen Signals Brazilian Intent with Bergamo Acquisition
9.13.9 Gilead, Novo Nordisk, Biogen, UCB and Meizler
9.13.10 Other Top Japanese Companies Trail Behind Takeda in Brazil
9.14 Will Multinational Generics Leaders Compete in Brazil?
9.14.1 Teva Pharmaceutical Industries: Generics Giant Targets Brazil
9.14.2 Mylan: Agila Acquisition Boosts Brazilian Strategy
9.14.3 Actavis: Newly-Merged Player May Target Brazil
9.14.4 Ranbaxy Hands Over to Daiichi, but Other Indian Companies Still in the Hunt in Brazil
9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
9.14.6 Valeant: M&A Drive Into the Market
9.15 Brazil as a Pharmaceutical Research Destination

10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2015-2025

10.1 Strengths, Weaknesses, Opportunities, Threats within the Market, and Political, Social, Economic and Technological Factors
10.2 A Crucial Market for the Pharmaceutical Industry
10.3 Governmental Regulation Remains an Issue
10.4 One of the Highest Pharmaceutical Tax Rates in the World
10.5 Room to Expand in Therapeutic Areas and Geographical Regions
10.6 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
10.7 Large and Ageing Population Eager to Buy Medicines
10.8 Improved Self-Sufficiency, Biotechnological and Digital, Among Government’s Goals
10.9 Economic Conditions in 2015 - Can Economic Growth Keep Pace With Healthcare Costs?
10.10 Political Environment a Decisive Influence on the Market

11. Research Interview

11.1 Interview with Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
11.2 On Gaining Access to the Brazilian Market, Achieving Success and Factors That Differentiate Brazil from Other Markets
11.3 The Brazilian Generics and Biosimilars Market, and Biocad’s Progress on its Biosimilars for Brazil
11.4 Biocad’s Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
11.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
11.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market- and How the 2016 Olympics will Compare
11.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses will Improve in Coming Years

12. Conclusions from the Research and Analysis

12.1 Brazil Likely to Grow Faster than Most Other Top 10 Pharmaceutical Markets
12.2 Generics to be the Fastest-Growing Segment
12.3 Technology Transfer Crucial to Patented Drugs Market
12.4 Generics: Opportunities for Multinationals?
12.5 Cancer Treatment: Biggest Therapeutic and Commercial Opportunity
12.6 Concluding Remarks

List of Tables

Table 1.1 Brazilian Pharmaceutical Market Forecast by Therapy Area: Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 1.2 Brazilian Pharmaceutical Market Forecast by Therapy Area: Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 1.3 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Brazilian Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2013-2018
Table 2.2 Brazilian Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2019-2025
Table 2.3 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2014
Table 2.4 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2014
Table 2.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2014
Table 3.1 World’s Largest Pharmaceutical Markets: Revenues ($bn), Market Shares (%), 2013
Table 3.2 Latin America’s Largest Pharmaceutical Markets: Revenues ($bn), Market Shares (%), 2013
Table 3.3 Pharmerging Markets
Table 4.1 Members of FenaSaúde (in Portuguese, with English in brackets), 2014
Table 6.1 Patented Prescription Drugs, Generics and OTC Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2013-2025
Table 6.2 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2018
Table 6.3 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2025
Table 6.4 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2025
Table 6.5 Prescription Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 6.6 Selected Technology Transfer Agreements in Brazil, 1985-2013
Table 6.7 Generic Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%). 2015-2025
Table 6.8 OTC Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.1 Therapeutic Areas in the Brazilian Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2013-2025
Table 7.2 Brazilian Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2018
Table 7.3 Brazilian Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2025
Table 7.4 CNS Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.5 Cardiovascular Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.6 Alimentary/Metabolic Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.7 Oncology Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.8 Infectious Diseases Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.9 Other Therapeutic Areas: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenues ($bn), Market Share (%), 2014
Table 8.2 EMS Overview, 2015
Table 8.3 Hypermarcas Overview, 2015
Table 8.4 Medley Overview, 2015
Table 8.5 Aché Overview, 2015
Table 8.6 Eurofarma Overview, 2015
Table 8.7 Teuto Overview, 2015
Table 8.8 Biolab Farmacêutica Overview, 2015
Table 8.9 Biolab Farmacêutica Pipeline, 2015
Table 8.10 Cristalia Overview, 2015
Table 8.11 Libbs Overview, 2015
Table 8.12 União Química Overview, 2015
Table 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2014
Table 9.2 Selected Multinational M&A Activity in the Brazilian Market, 2009-2012
Table 9.3 Sanofi Overview, 2015
Table 9.4 Novartis Overview, 2015
Table 9.5 Roche Overview, 2015
Table 9.6 Merck & Co Overview, 2015
Table 9.7 Pfizer Overview, 2015
Table 9.8 Takeda Overview, 2015
Table 9.9 Bayer Overview, 2015
Table 9.10 AstraZeneca Overview, 2015
Table 9.11 Boehringer Ingelheim Overview, 2015
Table 9.12 Merck KGaA Overview, 2015
Table 10.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2015
Table 10.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2015
Table 10.3 Brazilian Pharmaceutical Market: STEP Analysis, 2015

List of Figures

Figure 1.1 Product Segments Covered Within the Brazilian Pharmaceutical Market
Figure 1.2 Therapeutic Areas Covered Within the Brazilian Pharmaceutical Market
Figure 2.1 Brazilian Pharmaceutical Market: Revenues ($bn), 2013-2025
Figure 2.2 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2014
Figure 2.3 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2014
Figure 2.4 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2014
Figure 3.1 Top Ten Global Economies, 2013
Figure 3.2 Top Ten Global Economies, 2023
Figure 3.3 World’s Largest Pharmaceutical Markets by Revenue Share, 2013
Figure 3.4 Latin America’s Largest Pharmaceutical Markets by Revenue Share, 2013
Figure 3.5 BRIC Nations Pharmaceutical Market Revenues ($bn), 2013
Figure 4.1 Brazilian Public vs Private Healthcare, 2014
Figure 4.2 CMED-Mandated Average Price Rises, 2010-2014
Figure 5.1 Doctors per 1,000 Inhabitants by Brazilian Region, 2013
Figure 5.2 Brazil: Regional Population Shares (%), 2012
Figure 5.3 Brazilian Pharmaceutical Market Shares (%) by Region, 2012
Figure 5.4 Brazilian GDP Shares (%) by Region, 2012
Figure 6.1 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2018
Figure 6.2 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2025
Figure 6.3 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2025
Figure 6.4 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), 2013, 2018, 2025
Figure 6.5 Patented Prescription Drugs Segment Revenue ($bn), 2013-2025
Figure 6.6 Drivers and Restraints for Patented Pharmaceuticals, 2015
Figure 6.7 Generic Drugs Segment Revenue ($bn), 2013-2025
Figure 6.8 Drivers and Restraints for Generic Drugs, 2015
Figure 6.9 Brazilian Biologics Market Breakdown: Revenues ($bn) and Market Shares (%), 2013
Figure 6.10 Brazilian Biologics Market Breakdown: Revenues ($bn), 2013, 2019, 2025
Figure 6.11 OTC Drugs Segment Revenue ($bn), 2013-2025
Figure 6.12 Drivers and Restraints for OTC Drugs, 2015
Figure 7.1 Brazilian Market: Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2018
Figure 7.2 Brazilian Market: Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2025
Figure 7.3 Therapeutic Area Breakdown: Revenues ($bn), 2013-2025
Figure 7.4 Therapeutic Area Breakdown: Revenues ($bn), 2013, 2018, 2025
Figure 7.5 CNS Therapeutic Area: Revenues ($bn) 2013-2025
Figure 7.6 Drivers and Restraints for CNS Conditions, 2015
Figure 7.7 Cardiovascular Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.8 Drivers and Restraints for the Cardiovascular Therapy Area, 2015
Figure 7.9 Alimentary/Metabolic Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.10 Drivers and Restraints for the Alimentary/Metabolic Therapy Area, 2015
Figure 7.11 Oncology Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.12 Cancer Incidence in Males in Brazil: Numbers of Cases, 2014
Figure 7.13 Cancer Incidence in Males in Brazil: Shares (%), 2014
Figure 7.14 Cancer Incidence in Females in Brazil: Numbers of Cases, 2014
Figure 7.15 Cancer Incidence in Females in Brazil: Shares (%), 2014
Figure 7.16 Drivers and Restraints for the Oncology Therapeutic Area, 2015
Figure 7.17 Infectious Diseases Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.18 Drivers and Restraints for the Infectious Disease Therapeutic Area, 2015
Figure 7.19 Other Therapeutic Areas: Revenue ($bn), 2013-2025
Figure 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenues ($bn), Market Share (%), 2014
Figure 8.2 Ache Product Portfolio Breakdown (%), 2013
Figure 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2014
Figure 12.1 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2013-2018
Figure 12.2 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2019-2025
Figure 12.3 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2018
Figure 12.4 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), 2019-2025
Figure 12.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), 2014
Figure 12.6 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), 2013-2018
Figure 12.7 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), 2019-2025

掲載企業リスト

Companies Listed

Abbott
Abbvie
ABRAFARMA (Associação Brasileira das Redes de Farmácias e Drogarias)
Aché
Actavis
Agila Specialties
Allianz Saúde
Alteogen
American Diabetes Association
AmerisourceBergen Corporation
Amgen
Amil Participações
ANS (Agência Nacional de Saúde Suplementar)
Antaris Consulting
ANVISA
Arcolab
Arena Pharmaceuticals
Associação Brasileira de Reabilitação de Coluna
Associação Nacional de Assistencia ao Diabetico
Astellas
AstraZeneca
Athos Farma
Axis Biotec
Baxter
Bayer
Bergamo
Bill & Melinda Gates Foundation
Biocad
BiocadBrazil Farmaceutica
Biocon
Biogen
Biolab Emcure
Biolab Farmacêutica
Biomanguinhos
Biomm
Bionovis
Biosintética
BNDES (The Brazilian National Bank for Economic and Social Development)
Boehringer Ingelheim
Boiron
Brainfarma Industria e Farmaceutica
Brasil Pharma
Brazilian Medical Association
Bristol-Myers Squibb
BTG Pactual
Bunker Industria Farmaceutica
Butantan Institute
Care Plus Medicina Assistencial
CEBR (Centre for Economics and Business Research)
Ceitec
Celesio
Chemo
Claris Lifesciences
CMED (Câmara de Regulação do Mercado de Medicamentos)
Corporacion Infarmasa
Cosmed Industria de Cosmeticos e Medicamentos
Cristália
CVS Pharmacy
Daiichi Sankyo
Dimed
DM Industria Farmaceutica
DPSP SA
Eli Lilly
Emcure
Empresas Andromaco
EMS
Eurofarma
Everis
Farmácia Popular
Farmais
Farmalife
Farmanguinhos
FDA (US Food and Drug Administration)
Federal Council of Medicine
FenaSaúde
Fiocruz
Forest Laboratories
FUNED (Fundação Ezequiel Dias)
Gama Saúde
Germed Pharma
Gilead
GlaxoSmithKline (GSK)
Glenmark
Golden Cross
Grunenthal
Grupo Amil Saúde
Grupo Bradesco Saúde
Grupo Caixa Seguros Saúde
Grupo Cimed
Grupo Intermédica
Grupo SulAmérica Saúde
Grupo Tempo Saúde
GTPI (The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples)
Hapvida Assistência Médica
Health Canada
Hebron
Hemobras
Horizon Pharma
Hospital das Clínicas
Hospital Israelita Albert Einstein
Hospital Santa Catarina
Hypermarcas
IESS (Instituto de Estudos de Saúde Suplementar)
IMA Laboratories
Indar Institute
Indian Council of Medical Research
Innova
INSS (The Brazilian National Institute of Social Security)
Instituto Terapeutico Delta
Instituto Vital Brazil
InterFarma
Itauseg Saúde
Johnson & Johnson
Kantar Health
Kenya Medical Research Institute
Laboratório Daudt Oliveira
Laboratórios Klinger Do Brasil
LAFEPE (Laboratório Farmacêutico do Estado de Pernambuco)
Laprin
Lazard
Legrand
Libbs
Libbs Biotec
Luper Indústria Farmacêutica
mAbxience
Malaysian Ministry of Health
Mantecorp Industria Quimica e Farmaceutica
Marítima Saúde Seguros
Medley
Meizler Biopharma
Merck & Co.
Merck KGaA
Merz
Metlife Exclusivamente Odontológicos
Minas Gerais State Department of Health
Ministry of Health
Moksha8
MSF (Médecins sans Frontières)
Multilab Industria e Comercio de Productos Farma
Mundipharma
Mylan
Nature's Plus Farmacêutica
NeoQuimica
Novartis
Novo Nordisk
Nycomed
Odontoprev
Omint Serviços de Saúde
Oncoprod
Orygen
Otsuka
Pan American Health Organisation
Panarello
Panpharma
Pasteur Institute of France
Pele Nova
Pfizer
PharmaPraxis
Piramal
Porto Seguro - Seguro Saúde
Probiomed
Probiotica
Profarma
Profarma Speciality
Pró-Genéricos
Protalix Biotherapeutics
Quesada Farmacêutica
Quintiles
Raia Drogasil
Ranbaxy
Reckitt Benckiser
Roche
Sandoz do Brasil Indústria Farmacêutica
Sanobiol
Sanofi
Shasun Pharma
Sincamesp
Sinclair IS Pharma
Sistema Único de Saúde (SUS)
Sindusfarma
Sun
Supera Farma Laboratorios
Takeda
Tamoio
Tecpar
Telefônica Digital
Teuto
Teva Pharmaceutical Industries
The Sabin Vaccine Institute
The World Bank
TKS Farmacêutica
Torrent
UCB (Union Chimique Belge)
UERJ (Universidade do Estado do Rio de Janeiro)
União Química
UNICAMP (Universidade Estadual de Campinas)
Unimed Seguros Saúde
University of São Paulo
Valeant
Walgreens
Warc
Watson
WHO (World Health Organization)
Wockhardt
Zydus Cadila

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

LinkIcon中国の医薬品市場2014-2024年

中国の医薬品市場は2014年に全体で974億ドルに達し、2024年にかけて拡大が続くと予測しています

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。